Governmental Funding Sample Clauses

Governmental Funding. Except as specified in Schedule 3.1(p), the Company and the Subsidiary have no pending or outstanding grants, incentives, exemptions or subsidies from the Government of the State of Israel or any agency thereof, or from any non-Israeli governmental entity, granted to the Company or the Subsidiary or assigned to or assumed by the Company or the Subsidiary (collectively, “Grants”), including, without limitation, (i) the Israeli Investment Center, (ii) the Israeli Office of the Chief Scientist, (iii) the BIRD Foundation and any other similar governmental or government-related entity, (iv) the Fund for the Encouragement of Marketing, and (v) any taxation authority.

Governmental Funding. Other than as listed in Schedule (mm), the Company has not applied, obtained or received any grant, loan, incentives, benefits (including tax benefits), subsidies or other assistance from any governmental or regulatory authority or any agency, or any international or bilateral fund, institute or organization or public entities or authorities, including, from the IIA. The Company is an “approved enterprise” within the meaning of the Israeli Encouragement of Capital Investments Law, 1959. The Company was and is in compliance, in all material respects, with the terms and conditions of any such recognitions, grants or benefits. Other than as set forth in Schedule 3.1(mm) of the Disclosure Schedule, no royalties, interest, participation fees or other payments are payable or will be payable by the Company as a result of such grants or benefits. The consummation of the transactions contemplated hereby will not affect the continued qualification for such grants or benefits, the terms or duration thereof or require any reimbursement, repayment, refund or cancellation of any previously claimed or received grants or benefits.

Governmental Funding. Except as set forth in Schedule 8.22(i) of the Disclosure Schedule, the Company has not received and has not applied for any grants, incentives, benefits (including tax benefits) and subsidies from any Israeli or foreign governmental or regulatory authority or any agency thereof, including the IIA, nor filed any application for grants under the Law for Encouragement of Industrial Research and Development, 1984 (the “R&D Law”), or under any bi-national or multinational research and development cooperation agreement including the Binational Industrial Research and Development Foundation etc. (collectively, “Government Grants”) nor does it currently intend to submit any application for any of the foregoing. Schedule 8.22(i) of the Disclosure Schedule sets forth: (a) the aggregate amount of each Government Grant; (b) the aggregate outstanding obligations, if any, of the Company under each Government Grant with respect to royalties or other payments; and (c) the outstanding amounts to be paid to the applicable governmental entity, if any. The Company is not in violation of any of the Government Grants, including with respect to timely payment of any royalty obligations. Except as set forth in Schedule 8.22(ii)of the Disclosure Schedule, the Company has complied with all obligations in connection with such Government Grants, including the R&D Law and the regulations promulgated thereunder and the guidelines, circulars and rules issued by the IIA. No claim or challenge has been made by any governmental authority with respect to the Company’s entitlement to the Government Grants or the compliance of the Company with the terms, conditions, obligations or undertakings relating thereto. The consummation of the Agreement and other Related Agreements (including the exercise by the Purchaser of the Purchaser Option under the Share Purchase Option Agreement (as defined therein)) and the transactions contemplated hereby and thereby will not in of themselves adversely affect the continued qualification for the Government Grants or the terms or duration thereof or require any recapture of any previously claimed Government Grants or any payments to any governmental body in connection with any Government Grants. Except as provided in Schedule 8.22(iii) of the Disclosure Schedule, no Government Grants imposes any restrictions or limitations on the development or use of, or any encumbrance on, any Owned Intellectual Property or gives the grantor of such Government Grants any ri...

Governmental Funding. Except as set forth in Schedule ‎8.9 of the Disclosure Schedule, the Company has not received and has not applied for any grants, incentives, benefits (including tax benefits) or subsidies from any governmental or regulatory authority or any agency thereof, including the Investment Center and the Israel Innovation Authority (the “IIA”) (all grants listed in Schedule ‎8.9 of the Disclosure Schedule, the “Grants”). Except as set forth in Schedule ‎8.9 of the Disclosure Schedule attached hereto, the Company is in full compliance with all respective provisions, terms and conditions applicable to such Grants, including, inter alia, the filing of all reports and requests, and the application for and obtainment of all consents and approvals, required to be filed, applied for or obtained, as applicable, under any of the foregoing or under any applicable law, statute, regulation or otherwise in connection with any transactions consummated by the Company at any time prior to the date hereof. The Company has no outstanding monetary obligations to the IIA that have not been paid in full and the consummation of the transactions contemplated hereby will not affect the continued qualification for such grants or benefits, the terms or duration thereof or require any reimbursement, repayment, refund or cancellation of any previously claimed or received grants or benefits. No claim or challenge has been made by the IIA with respect to the Company’s entitlement to such grants, or the compliance with the terms, conditions, obligations or laws relating to such grants and to the Company’s knowledge, the IIA is not expected to make any claims in connection with the Company’s obligations or restrictions under the IIA’s related laws, rules and guidelines.

Governmental Funding. The Company and/or the Company Subsidiaries have applied for and received financial assistance from the Israeli Authority of Technology Innovation and the Office of the Chief Scientist of the Israeli Ministry of the Economy (the “Innovation Authority”), including incentives from the Government of the State of Israel or any agency thereof, granted to the Company or to any Company Subsidiary (including any grant of “approved/privileged enterprise” status under the Israeli Law for the Encouragement of Capital Investment, 5719-1959 (the “Investment Center”)). Neither the Company nor any Company Subsidiary has received any notice of termination or revocation of any subsidies, grants, and incentives from the Government of the State of Israel or any agency thereof, or from any other Governmental Authority, granted to it or for which it has an outstanding application from the Innovation Authority.

Governmental Funding. Except as set forth in ‎Section 4.16(m) of the Company Disclosure Letter, no funding, facilities or resources of a Governmental Entity, university, college, other educational institution or research center or funding from third parties was used in the development of the Intellectual Property owned or purportedly owned by the Company or its Subsidiary or, to the Knowledge of the Company, exclusively licensed to the Company, and no such Governmental Entity, university, college, other educational institution or research center has, to the Knowledge of the Company, any claim or right in or to such Intellectual Property.

Governmental Funding. The Company has not applied, obtained or received any grant, loan, incentives, benefits (including tax benefits), subsidies or other assistance from any governmental or regulatory authority or any agency, or any international or bilateral fund, institute or organization or public entities or authorities, including, from the IIA, nor is the Company an “approved enterprise”, “benefited enterprise” or “preferred enterprise” within the meaning of the Israeli Encouragement of Capital Investments Law, 1959, other than as set forth in Schedule 3.1(oo) of the Disclosure Schedule. The Company was and is in compliance, in all material respects, with the terms and conditions of any such grants or benefits. Other than as set forth in Schedule 3.1(oo) of the Disclosure Schedule, no royalties, interest, participation fees or other payments are payable or will be payable by the Company as a result of such grants or benefits. The consummation of the transactions contemplated hereby will not affect the continued qualification for such grants or benefits, the terms or duration thereof or require any reimbursement, repayment, refund or cancellation of any previously claimed or received grants or benefits.

Governmental Funding. Iceland Title Objective(s) Timeframe 1999 - 2001

Governmental Funding. Except as set forth in Section 4.25 of the Disclosure Schedules, the Sellers have not applied for or received any direct financial assistance, grants, Tax benefits, incentives and subsidies from any Governmental Authority, including the OCS (“Grants”) with respect to the Purchased Assets and Assumed Liabilities, and no funding from a Governmental Authority was used in the development of the Intellectual Property Assets or its products and services. Section 4.25 of the Disclosure Schedules also details all material undertakings of the Sellers given in connection with the Grants. Each Seller is in compliance, in all material respects, with the terms and conditions of its Grants (including, without limitation, the Law for the Encouragement of Industrial Research and Development 5744-1984, as amended from time to time) and, except as disclosed in Section 4.25 of the Disclosure Schedules, has duly fulfilled, in all material respects, all the undertakings relating thereto. The Sellers have not received any notice of termination or revocation of any Grants granted to a Seller and to any Subsidiary or for which the Sellers have an outstanding application from the OCS, in each case solely with respect to the Business and to the Knowledge of the Sellers, no event has occurred and no circumstances exist which is reasonably likely to lead to the revocation or material modification of any of the Grant.